Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Genetics

Building Your Care Team & Long-Term Monitoring

At a Glance

Managing Cerebrotendinous Xanthomatosis (CTX) requires a multidisciplinary medical team to monitor CDCA therapy. Long-term success depends on tracking serum cholestanol and bile alcohol levels, rather than relying solely on brain MRIs, which may not reflect physical improvements.

Managing Cerebrotendinous Xanthomatosis (CTX) is not a solo effort; it requires a lifelong partnership with a team of experts. Because the disease affects so many different systems—from your eyes to your brain to your digestive tract—success depends on a coordinated “multidisciplinary” approach [1][2].

Assembling Your Expert Team

A comprehensive care team for CTX should include specialists who understand both the biochemical and physical aspects of the disease:

  • Metabolic Specialist or Geneticist: Often the team lead, this doctor manages the overall biochemical balance and the CDCA therapy [1].
  • Neurologist: Focuses on protecting the brain and spinal cord, managing symptoms like ataxia (balance issues) or spasticity (muscle stiffness) [3][4].
  • Genetic Counselor: Helps you navigate family testing, understand the genetics of the disease, and assist with reproductive planning.
  • Ophthalmologist: Monitors for cataracts and other eye-related issues [3][5].
  • Gastroenterologist: Addresses chronic diarrhea and monitors liver health, which is vital while taking bile acid replacement therapy [2].
  • Psychiatrist or Neuropsychologist: Manages the behavioral and cognitive symptoms, such as irritability or difficulty focusing [6][7].

Vetting Your Doctors

Since CTX is rare, you may need to ensure your providers have the necessary expertise. Consider asking:

  1. “How do you track the effectiveness of CDCA beyond just looking at a standard cholesterol panel?” (The answer should involve cholestanol or bile alcohol levels) [8].
  2. “Are you aware of the risks of interrupting my medication, and how do we handle insurance or supply delays?” [8][9].
  3. “Which biochemical markers do you consider the most sensitive for my specific case?” [10][11].

Long-Term Surveillance: The “Check-Up” Routine

Monitoring CTX is a two-part process: checking the body’s chemistry and checking the body’s structure.

Biochemical Monitoring

Regular blood and urine tests are the most important tools for ensuring your dose of CDCA is correct.

  • Serum Cholestanol: This is the primary marker. The goal is to keep this level as low as possible to prevent further neurotoxicity [8][12].
  • Bile Alcohol Levels: Specialized urine tests (measuring markers like GlcA-tetrol) can provide an even more sensitive look at how well the metabolic pathway is being “shushed” by the medication [10][11].

Imaging and the Brain MRI

Most CTX patients will have regular brain MRIs. However, it is important to manage your expectations regarding these scans:

  • The MRI Paradox: Conventional MRI scans often show “static” damage (like hypersignals in the dentate nuclei of the brain) that may not change even when you feel much better clinically [13][12].
  • Clinical vs. Structural: You may experience significant improvements in memory, mood, or walking while your MRI looks exactly the same as it did a year ago [14].
  • Advanced Imaging: Newer techniques like Diffusion Kurtosis Imaging (DKI) are being explored because they are more sensitive to subtle white matter changes that conventional MRIs might miss [15].

Living with a Rare Disease: The Psychological Toll

Living with a chronic, rare condition often brings a unique form of anxiety, sometimes called “scanxiety”—the fear surrounding test results and imaging [16].

It is helpful to remember that the main goal of treatment is stability. While we all hope for total reversal of symptoms, stopping the disease from progressing further is a major medical victory [8][17]. If your biochemical markers (cholestanol) are stable and your daily function is maintaining or improving, the treatment is doing its job, even if the MRI stays the same. Having a team that supports both your physical health and your mental well-being is the key to a high quality of life [18][17].

Common questions in this guide

What kind of doctors should be on my CTX care team?
A comprehensive CTX care team should include a metabolic specialist or geneticist, a neurologist, an ophthalmologist, a gastroenterologist, and a psychiatrist or neuropsychologist. This multidisciplinary approach ensures all systemic aspects of the disease are addressed.
How do doctors monitor if my CDCA treatment is working?
Doctors track the effectiveness of CDCA therapy by measuring serum cholestanol levels in your blood and bile alcohol markers in your urine. Keeping these biochemical markers as low as possible is the best way to prevent further neurological damage.
Why does my brain MRI look the same even though my CTX symptoms are improving?
Conventional brain MRIs often show static damage that doesn't change, even when your memory, mood, or balance noticeably improve. Because of this 'MRI paradox', doctors rely more on your clinical progress and bloodwork to judge if the treatment is working.
What is the main goal of long-term CTX treatment?
The primary goal of long-term treatment is disease stability. While symptom reversal is possible, stopping the disease from progressing further and maintaining your daily physical and mental function is considered a major medical victory.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many CTX patients have you managed, and are you familiar with the specific monitoring protocol for CDCA therapy?
  2. 2.Which biochemical lab do you use for cholestanol testing, and do they also measure bile alcohol markers like GlcA-tetrol?
  3. 3.In your experience, how do you correlate my clinical improvement with what you see—or don't see—on my conventional MRI scans?
  4. 4.Are you able to use advanced imaging like Diffusion Kurtosis Imaging (DKI) to get a more detailed look at my brain health?
  5. 5.How will our care team communicate between the neurologist, ophthalmologist, and GI specialist to ensure we aren't missing any systemic changes?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Progressive ataxia of cerebrotendinous xanthomatosis with a rare c.255+1G>T splice site mutation: A case report.

    Chang YY, Yu CQ, Zhu L

    World journal of clinical cases 2022; (10(29)):10681-10688 doi:10.12998/wjcc.v10.i29.10681.

    PMID: 36312475
  2. 2

    Sterol 27-Hydroxylase Deficiency as a Cause of Neonatal Cholestasis: Report of 2 Cases and Review of the Literature.

    Lipiński P, Klaudel-Dreszler M, Ciara E, et al.

    Frontiers in pediatrics 2020; (8()):616582 doi:10.3389/fped.2020.616582.

    PMID: 33520900
  3. 3

    Cerebrotendinous Xanthomatosis, a Treatable Disorder Often Missed: Case Series of Three Patients Confirmed by Genetic Testing.

    Yaqoob A, Dar WR, Raina A, et al.

    Neurology India 2024; (72(1)):138-141 doi:10.4103/ni.ni_1093_21.

    PMID: 38443015
  4. 4

    Cerebellar hypometabolism with normal structural findings in Cerebrotendinous xanthomatosis. A case report.

    Ragno M, Di Marzio F, Fuccio C, et al.

    Clinical neurology and neurosurgery 2015; (139()):221-3.

    PMID: 26519892
  5. 5

    Early diagnosis for cerebrotendinous xanthomatosis with juvenile cataract and family history.

    Öncel Acır N, Taskiran Kandeger B

    Ophthalmic genetics 2023; (44(4)):361-365 doi:10.1080/13816810.2023.2197492.

    PMID: 37017268
  6. 6

    Case report: Cerebrotendinous Xanthomatosis masquerading as adult ADHD in psychiatric practice.

    Kim J, Hong YJ, Lee SB, et al.

    Frontiers in psychiatry 2025; (16()):1528204 doi:10.3389/fpsyt.2025.1528204.

    PMID: 39967585
  7. 7

    Cognitive impairment in children and adults with cerebrotendinous xanthomatosis: A French cohort study.

    Salardaine Q, Shor N, Villain N, et al.

    Journal of inherited metabolic disease 2024; (47(5)):1069-1079 doi:10.1002/jimd.12765.

    PMID: 38897600
  8. 8

    Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study.

    Kisanuki YY, Nobrega PR, Himes R, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2025; (27(7)):101449 doi:10.1016/j.gim.2025.101449.

    PMID: 40297984
  9. 9

    Spinal cerebrotendinous xanthomatosis: A case report and literature review.

    Atallah I, Millán DS, Benoît W, et al.

    Molecular genetics and metabolism reports 2021; (26()):100719 doi:10.1016/j.ymgmr.2021.100719.

    PMID: 33659184
  10. 10

    Pathophysiology and Treatment of Lipid Abnormalities in Cerebrotendinous Xanthomatosis: An Integrative Review.

    Ribeiro RM, Vasconcelos SC, Lima PLGSB, et al.

    Brain sciences 2023; (13(7)) doi:10.3390/brainsci13070979.

    PMID: 37508912
  11. 11

    Toward newborn screening of cerebrotendinous xanthomatosis: results of a biomarker research study using 32,000 newborn dried blood spots.

    Hong X, Daiker J, Sadilek M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(10)):1606-1612 doi:10.1038/s41436-020-0846-x.

    PMID: 32523054
  12. 12

    Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.

    Catarino CB, Vollmar C, Küpper C, et al.

    Journal of neurology 2018; (265(2)):388-393 doi:10.1007/s00415-017-8711-9.

    PMID: 29260356
  13. 13

    Achilles Tendon Xanthoma and Cholestanol Revealing Cerebrotendinous Xanthomatosis: A New Case Report.

    Ahmed Ghassem M, Mounach A, H Djossou J, et al.

    Case reports in rheumatology 2021; (2021()):6656584 doi:10.1155/2021/6656584.

    PMID: 34104504
  14. 14

    A case of Cerebrotendinous Xanthomatosis with spinal cord involvement and without tendon xanthomas: identification of a new mutation of the CYP27A1 gene.

    Gelzo M, Di Taranto MD, Bisecco A, et al.

    Acta neurologica Belgica 2021; (121(2)):561-566 doi:10.1007/s13760-019-01267-4.

    PMID: 31875301
  15. 15

    Using fiber tractography and diffusion kurtosis imaging to evaluate neuroimaging changes in patients with cerebrotendinous xanthomatosis after stopping chenodeoxycholic acid treatment for three years.

    Lee JJ, Chang CC, Chang WN

    Biomedical journal 2022; (45(5)):814-820 doi:10.1016/j.bj.2021.09.003.

    PMID: 34543727
  16. 16

    Living with Cerebrotendinous Xanthomatosis: Patient, Caregiver, and Expert Perspectives.

    Steiner RD, DeBarber A, Larson A, et al.

    Advances in therapy 2024; (41(2)):467-475 doi:10.1007/s12325-023-02687-8.

    PMID: 38110654
  17. 17

    The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.

    Verrips A, Dotti MT, Mignarri A, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(4)):943-949 doi:10.1007/s10072-019-04169-8.

    PMID: 31863326
  18. 18

    Case report: Cerebrotendinous xanthomatosis treatment follow-up.

    Ejsmont-Sowała K, Książek T, Maciorowska-Rosłan K, et al.

    Frontiers in neurology 2024; (15()):1409138 doi:10.3389/fneur.2024.1409138.

    PMID: 38952472

This page provides educational information on building a care team and long-term monitoring for Cerebrotendinous Xanthomatosis (CTX). It is not a substitute for professional medical advice, diagnosis, or treatment.

Get notified when new evidence is published on Cerebrotendinous xanthomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.